Invivyd Inc.

10/19/2024 | Press release | Distributed by Public on 10/19/2024 08:18

Results from a Phase 1 First in human Study of Pemivibart: an Extended–half life Monoclonal AntibodyHolmes et al. IDWeek. 2024.